Connor, Clark & Lunn Investment Management (CC&L)’s Adicet Bio ACET Stock Holding History

Connor, Clark & Lunn Investment Management (CC&L)’s Portfolio ACET Stock Details ACET Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q1	–	Sell	-3,198	Closed	-$49.2K	–	1385
2024 Q4	$49.2K	Sell	3,198 -8,102	-72%	-$153K	﹤0.01%	1373
2024 Q3	$260K	Sell	11,300 -2,001	-15%	-$44.8K	﹤0.01%	1277
2024 Q2	$258K	Sell	13,301 -12,717	-49%	-$341K	﹤0.01%	1218
2024 Q1	$978K	Buy	+26,018	New	+$1.08M	﹤0.01%	897
2022 Q4	–	Sell	-7,774	Closed	-$1.77M	–	1180
2022 Q3	$1.77M	Buy	7,774 +5,568	+252%	+$1.41M	0.01%	518
2022 Q2	$515K	Buy	2,206 +22	+1%	+$4.83K	﹤0.01%	766
2022 Q1	$698K	Buy	2,184 +481	+28%	+$111K	﹤0.01%	726
2021 Q4	$476K	Buy	+1,703	New	+$292K	﹤0.01%	807

Other funds holding ACET

OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return

TCM

Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return

RCM

RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Carlyle Group Washington, District of Columbia $10B AUM 10.61% 1-Year Est. Return

ACM

Aquilo Capital Management San Francisco, California $55.8M AUM 41.76% 1-Year Est. Return

Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

Blackstone Inc New York $25.6B AUM 26.83% 1-Year Est. Return

Connor, Clark & Lunn Investment Management (CC&L)'s ACET Position: Q1 2025 in Review

Connor, Clark & Lunn Investment Management (CC&L) sold out of Adicet Bio (ACET) in Q1 2025, closing a stake of 3,198 shares — an estimated $49.2K sold.

Connor, Clark & Lunn Investment Management (CC&L) first reported a position in ACET in Q4 2021 and held it in 8 quarters. The position peaked at $1.77M in Q3 2022. 56 funds tracked by Wall St. Rank hold ACET as of Q1 2025.

Connor, Clark & Lunn Investment Management (CC&L) reported no remaining Adicet Bio position as of Q1 2025 after selling out during the quarter.
Connor, Clark & Lunn Investment Management (CC&L) sold 3,198 Adicet Bio shares in Q1 2025, an estimated $49.2K.
Connor, Clark & Lunn Investment Management (CC&L) first reported a position in Adicet Bio in Q4 2021 and held it in 8 quarters.
Connor, Clark & Lunn Investment Management (CC&L)'s Adicet Bio position peaked at $1.77M in Q3 2022.
56 funds tracked by Wall St. Rank held Adicet Bio as of Q1 2025.

Based on Connor, Clark & Lunn Investment Management (CC&L)'s 13F filing for Q1 2025, filed 12 May 2025.